GlassScriptPhysician profile
Joice Aley Muckom
NPI 1790489797
$569.48
in general payments reported to CMS, 2019-2025
15 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $97.76 · 2024: $51.12 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203.97 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $67.24 | 2025 | |
| Exact Sciences Corporation | $49.10 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $35.33 | 2023-2025 | |
| Dexcom, INC. | $32.46 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $23.08 | 2025 | Auvelity |
| Stryker Corporation | $21.35 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Seqirus USA INC | $20.45 | 2025 | Flucelvax, Fluad |
| Alkermes, INC. | $20.11 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $17.89 | 2023 | Xarelto |
| Vertex Pharmaceuticals Incorporated | $17.54 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.05 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $15.25 | 2023 | Bexsero, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2025 | |
| Lilly USA, LLC | $13.80 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joice Muckom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.